Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Inventory (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Inventory for 15 consecutive years, with $448000.0 as the latest value for Q4 2025.

  • Quarterly Inventory fell 29.23% to $448000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $448000.0 through Dec 2025, down 29.23% year-over-year, with the annual reading at $448000.0 for FY2025, 29.23% down from the prior year.
  • Inventory hit $448000.0 in Q4 2025 for Guided Therapeutics, down from $583000.0 in the prior quarter.
  • In the past five years, Inventory ranged from a high of $648000.0 in Q3 2023 to a low of $448000.0 in Q4 2025.
  • Historically, Inventory has averaged $595550.0 across 5 years, with a median of $595500.0 in 2022.
  • Biggest five-year swings in Inventory: surged 1137.25% in 2021 and later decreased 29.23% in 2025.
  • Year by year, Inventory stood at $571000.0 in 2021, then fell by 4.03% to $548000.0 in 2022, then grew by 15.33% to $632000.0 in 2023, then grew by 0.16% to $633000.0 in 2024, then fell by 29.23% to $448000.0 in 2025.
  • Business Quant data shows Inventory for GTHP at $448000.0 in Q4 2025, $583000.0 in Q3 2025, and $595000.0 in Q2 2025.